Indrayani Biotech gets ₹13.90 cr tax demand quashed, sent back for fresh look

Tipsheet Editorial — Wed, 15 Jul 2026 17:18:45 GMT

The ITAT ruling removes an immediate liability equal to 22% of market cap for the nano-cap company, though the matter is remanded.

What’s new

ITAT quashed the First Appellate Authority's order on a ₹13.90 crore tax demand for AY23-24.
Matter remanded to the First Appellate Authority for fresh adjudication.
Immediate threat of a cash outflow equal to 22% of market cap is removed.

Why it matters

For a nano-cap with a market cap of just ₹63 crore (at the time of demand) and a stalled ₹50 crore rights issue, a ₹13.90 crore tax liability could have been crippling. The tribunal's intervention buys breathing room, though the final outcome remains uncertain.

What we’re watching

Fresh adjudication timeline and whether the demand is reduced or upheld.
Any update on the halted rights issue, as the company still needs capital.

The full read

Indrayani Biotech just got a ₹13.90 crore tax demand knocked back by the Income Tax Appellate Tribunal, a sum that at the time equaled 22% of its market cap. The tribunal quashed the earlier appellate order and sent the case for fresh adjudication, removing the immediate threat of a payout that could have crippled a nano-cap already sitting on a stalled ₹50 crore rights issue. The ruling is a clear positive: it changes the risk calculus for a company with ₹76 crore market cap, 1.89x debt-to-equity, and zero net profit in the latest quarter. But fresh adjudication means the tax cloud hasn't lifted, just paused. The real test remains whether Indrayani can get its capital raising back on track.

Primary source: BSE · NSE

Indrayani Biotech halts ₹50 cr rights issue indefinitely

Tipsheet Editorial — Mon, 22 Jun 2026 16:11:51 GMT

The ₹49.90 crore capital raise, critical for the NPA-classified nano-cap, was supposed to shore up its balance sheet. Now there is no timeline.

What’s new

Indrayani Biotech indefinitely postponed its ₹49.90 cr rights issue after two extensions.
The capital raise was critical for the company facing financial distress and NPA classification.
No revised timeline provided; committee will announce later.

Why it matters

For a nano-cap with a market cap of ₹83 crore, a rights issue of ₹49.90 crore is nearly existential. The indefinite postponement without a new timeline raises serious doubts about the company's ability to raise capital and service its debt. This is a material negative event for a company already under NPA stress.

What we’re watching

Whether the company provides a revised timeline or abandons the issue entirely.
Lender reaction. NPA classification may worsen if capital isn't raised.
Stock price response given the issue's size relative to market cap.

The full read

Indrayani Biotech wanted to raise ₹49.90 crore to fix its balance sheet. It was a make-or-break move. The issue was 60% of its entire market cap. After two extensions, the company has now postponed the rights issue indefinitely. No revised timeline. The Rights Issue Committee will 'decide later'. For a company already classified as an NPA, with a debt/equity ratio of 1.89 and a PAT that fell 67% in the trailing period, that silence is the story. The capital raise was supposed to shore up liquidity. Now there is no capital. The stock, at a market cap of ₹83 crore, may now face a reassessment of risk. This isn't a delay. It's a signal.

Primary source: BSE · NSE

Indrayani Biotech Ltd. (INDRANIB) — Tipsheet

Indrayani Biotech gets ₹13.90 cr tax demand quashed, sent back for fresh look

What’s new

Why it matters

What we’re watching

The full read

Indrayani Biotech halts ₹50 cr rights issue indefinitely

What’s new

Why it matters

What we’re watching

The full read